Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris

Inclusion Criteria

Informed subject consent will be obtained from those patients meeting the following inclusion criteria:

Male and female patients 18 years or older.
Clinical and/or histopathological diagnosis of PRP
Candidate for systemic therapy (PASI ≥ 10)
Body surface area of involvement ≥ 10%
Good general health as confirmed by medical history
Patients who are willing and capable of cooperating to the extent and degree required by the protocol; and
Patients who read and sign an approved informed consent for this study

Exclusion Criteria

Patients are to be excluded based on the following criteria:

Vulnerable study population
Pregnant or nursing women
Women planning a pregnancy within the study period
Human immunodeficiency virus (HIV) positivity
Known history of adverse reaction to Cosentyx
Known history of hepatitis B, hepatitis C, or tuberculosis
Personal or family history of inflammatory bowel disease